Patients with cancers characterized by ALK gene rearrangements are potential candidates for ALK inhibitor therapy. These rearrangements are found in a subset of NSCLC cases, as well as in certain types of lymphomas and neuroblastomas. Genetic testing is crucial to identify patients who might benefit from this targeted approach.